Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METANOVA: Metastasis-directed Radiotherapy for De-novo Oligometastatic Prostate Cancer
NCT06150417Phase 2Recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jul 2024
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Failure-Free Survival at 5 years. Started Jul 2024; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06150417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06150417.